Diabetes medications (rosiglitazone – Avandia) in same class carry different risks of heart failure, death – Older adults who take the diabetes medication rosiglitazone appear to have a higher risk of death and heart failure than those taking the related medication pioglitazone, according to a report in the November 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Bicuspid aortic valve is the most common congenital cardiac anomaly in the adult population, and these adults do not appear to have lower survival rates compared to the general population. – Young adults with a bicuspid aortic valve, a congenital heart abnormality, experience subsequent cardiac events but do not appear to have lower survival rates compared to the general population, according to a study in the September 17 issue of the Journal of the American Medical Association (JAMA).
Cardiac effects associated with breast cancer treatment appear lower with dose-dense delivery of conventional chemotherapy – A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.
The burden of financing and providing medical care for persons older than 65 in the United States having diagnosed diabetes is growing rapidly as a result of increased incidence and, especially, prevalence of diagnosed diabetes, decreased mortality, and overall lack of improvement in rates of complications in persons having diagnosed diabetes. – The prevalence of diabetes mellitus is growing worldwide. Consequently, there has been increased emphasis on primary and secondary prevention of diabetes. The annual number of Americans older than 65 newly diagnosed with diabetes increased by 23 percent between 1994 to 1995 and 2003 to 2004, according to a report in the January 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
R. Scott Braithwaite, M.D., and his colleagues developed a new method of evaluating medical screening tests like colonoscopy, called the “payoff time,” which is the minimum amount of time it takes for the benefits from a test to exceed its harms (i.e., its complications and side effects).
– Even though current guidelines advocate colorectal cancer screenings for those with severe illnesses, they may bring little benefit and may actually pose harm, according to a recent study by Yale School of Medicine researchers published in the Archives of Internal Medicine.
